We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04555096
Recruitment Status : Terminated (Participants are no longer receiving intervention)
First Posted : September 18, 2020
Results First Posted : March 18, 2022
Last Update Posted : March 18, 2022
Information provided by (Responsible Party):
Galera Therapeutics, Inc.

Brief Summary:
A Trial of GC4419 in Patients with Critical Illness due to COVID-19

Condition or disease Intervention/treatment Phase
Covid19 SARS-CoV-2 Infection Drug: GC4419 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)
Actual Study Start Date : September 9, 2020
Actual Primary Completion Date : May 28, 2021
Actual Study Completion Date : May 28, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Active GC4419
Arm A
Drug: GC4419
180 Minute IV Infusion
Other Name: Avasopasem

Placebo Comparator: Placebo
Arm B
Drug: Placebo
180 Minute IV Infusion

Primary Outcome Measures :
  1. 28 Day All-cause Mortality [ Time Frame: 28 days ]
    Death rate of patients with critical illness due to COVID-19 28 days after initiation of therapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects at least 18 years of age.
  2. Ability to understand and the willingness to sign a written informed consent.
  3. Laboratory-confirmed SARS-CoV-2 infection as determined by a positive PCR test documented prior to randomization
  4. Requirement for intensive inpatient hospital care
  5. Acute hypoxemic respiratory failure typifying ARDS
  6. Adequate liver function
  7. Use of effective contraception

Exclusion Criteria:

  1. Expected survival for less than 48 hours after randomization
  2. Child-Pugh stage C hepatic impairment and/or portal hypertension secondary to cirrhosis
  3. Stage IV chronic kidney disease or end-stage kidney disease on maintenance hemodialysis
  4. Requirement for extra-corporeal membrane oxygenation (ECMO)
  5. Acute Myocardial Infarction (AMI)
  6. Active bleeding requiring transfusion
  7. Concurrent participation in another clinical trial of experimental treatment for SARSCoV-2
  8. Female patients who are pregnant or breastfeeding
  9. Requirement for concurrent treatment with nitrates

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04555096

Layout table for location information
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Missouri
Saint Louis University
Saint Louis, Missouri, United States, 63110
Mercy Research
Saint Louis, Missouri, United States, 63141
Sponsors and Collaborators
Galera Therapeutics, Inc.
Layout table for investigator information
Study Chair: Jon Holmlund, MD Study Chair
  Study Documents (Full-Text)

Documents provided by Galera Therapeutics, Inc.:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Galera Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04555096    
Other Study ID Numbers: COV-4419-201
First Posted: September 18, 2020    Key Record Dates
Results First Posted: March 18, 2022
Last Update Posted: March 18, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Galera Therapeutics, Inc.:
SARS-CoV-2 Infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Critical Illness
Disease Attributes
Pathologic Processes
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Avasopasem manganese
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs